Objective Ventriculomegaly is the most common fetal brain anomaly identified during prenatal anatomy ultrasound.
INTRODUCTION
At 18 to 22 weeks' gestation, a detailed anatomy ultrasound (US) is commonly performed to investigate fetal growth and structural abnormalities. 1, 2 The goal is to identify structural anomalies to inform parents and allow them to make timely decisions regarding pregnancy. Ventriculomegaly (VM) is the most common fetal brain abnormality identified with a prevalence of 0.3 to 1.5 per 1000 live births. 3 VM is defined as an axial atrial width of the lateral cerebral ventricles equal to or in excess of 10 mm, which is greater than 4 standard deviations (SD) above the mean of 7.6 ± 0.6 mm. 1, 4, 5 VM is categorized as mild when the ventricle width is 10 to 15 mm or severe when it exceeds 15 mm. 6 Some researchers subdivide the measurements into 10 to 12 mm indicating mild dilation and 12 to 15 mm being moderate. [7] [8] [9] [10] We chose to use the more commonly accepted measurements of 10 to 15 mm dilation defining mild VM, [11] [12] [13] [14] [15] [16] particularly in light of the meta-analysis by Melchiorre et al. demonstrating the lack of significant difference in neurologic prognosis between the two groups. 17 Usually both ventricles are involved, but the presentation may also be unilateral or asymmetrical. VM may be isolated or present in association with additional US-detected structural anomalies, which we are defining as complex VM. Isolated VM by definition is a diagnosis of exclusion and characterized by ventricular dilation presenting with no associated malformations or markers for aneuploidy evident at initial US scan. 4, 6 With such a broad spectrum of VM presentations and associated findings, it can be difficult to determine the significance and prognosis of a diagnosis of VM. Ventriculomegaly may be a benign finding lacking pathological significance, particularly in cases of isolated mild VM (imVM), 7, 18 or it may be indicative of a more severe prognosis and can be associated with chromosomal abnormalities, congenital infection, cerebral vascular accident, or other fetal abnormalities both neurologic and extraneurologic, as well as developmental delay. 5, 19 Cases of severe VM are more likely to have such associations 20, 21 and more clearly carry a poor prognosis with significant morbidity and mortality. 22, 23 Although cases of imVM seem less critical, they are complicated by uncertainty of etiology and prognosis making parental counseling and pregnancy management difficult.
Identification of VM prompts additional testing for the presence of associated abnormalities and investigates etiology to provide information on fetal prognosis. Currently, there is no uniform protocol as to how to manage cases of VM, particularly when the dilation is mild and there are no anomalies identified on initial US. Tests that may be performed include magnetic resonance imaging (MRI), testing for aneuploidy, and congenital infection screening.
The literature regarding the utility of imaging studies to further characterize the clinical picture and diagnostic followup testing to better identify the etiology of the imVM is not consistent. For example, some authors describe fetal MRI as important follow-up to a diagnosis of imVM, 5, 12, 20, 21, [24] [25] [26] while others describe MRI as providing only marginal superiority over US. 9, 12, 16, 17 The heterogeneous presentation of VM, in addition to multiple ancillary testing options and uncertainty regarding their utility, makes managing these cases particularly complicated. The aim of our study was to provide a descriptive analysis of cases of mild VM presenting to our tertiary referral center. We also investigated the provision and utility of ancillary tests subsequent to the identification of mild VM by comparing the frequency of positive follow-up tests in the presence or absence of additional US findings. We aim to provide a more accurate risk assessment to aid in counseling families and inform pregnancy management.
METHODS
We retrospectively reviewed all cases of cerebral VM presenting to a tertiary prenatal referral center between September 2009 and June 2015. We identified 153 cases through querying the institutional obstetrical US electronic database for all pregnancies in which a cerebral ventricle measurement of ≥10 mm was recorded ( Figure 1 ). All ventricular measurements were obtained with a transabdominal US probe according to the International Society of Ultrasound in Obstetrics and Gynecology guidelines. 1 The atrial axial width at the level of the glomus of the choroid plexus was measured by placing calipers inside the echoes generated by the medial and lateral ventricular walls. 1 The measurement was obtained perpendicular to the ventricular axis in the transventricular axial plain. Both lateral ventricles were measured in order to characterize unilateral and bilateral dilation as well as symmetry between the ventricles. Symmetry between ventricle dilation was defined as measurement difference of ≤2 mm, in accordance with previous work. 35, 36 All US scans were performed using GE Voluson E8 with 3-to 8-mHz probes by RDMS certified technicians. Excluded were cases of severe VM (>15 mm). Although 15 mm is often accepted as the lower limit of severe VM, 6 we decided to include these cases in our study population owing to the assumed rounding of US measurements. Any measurement ≥15.1 mm was considered severe and excluded from the study. A detailed review of the US at the time of initial VM detection was performed by maternal-fetal medicine physicians to identify any associated intracranial or extracranial abnormalities. This review included fetal heart views and echocardiography when indicated, and abnormalities were Figure 1 Flow chart of included cases of mild ventriculomegaly analyzed on the basis of organ system involvement and syndromic association. On the basis of this assessment, cases were then classified as either isolated or complex VM.
Following the initial identification of VM, women were counseled and a variety of ancillary tests were performed. Tests included additional imaging by MRI, fetal genetic testing for chromosomal abnormality, and maternal serology infection screening. MR sequences included standard single-shot fast spin-echo T2-weighted sequences in multiple planes and T1-weighted sequences. Genetic testing was performed with amniocentesis in a subset of patients and included karyotype, fluorescence in situ hybridization (FISH), and microarray analysis. Screening genetic testing, specifically noninvasive prenatal testing, was not included in this study because it was not consistently in use or electronically documented during the study period at our site. Serologic perinatal infection screening for cytomegalovirus (CMV), herpes simplex virus 1 and 2 (HSV1 and HSV2), toxoplasma, rubella, parvovirus B19, Ebstein-Barr virus, and enterovirus was also offered. The findings from these tests were reviewed by maternal-fetal medicine physicians and radiologists with experience in reviewing prenatal MRI scans.
Chi-squared analysis was used for categorical data; Fisher's exact test was used for chi-squared analysis when any of the groups analyzed contained less than five events; and Student's t-test was used for analysis of continuous variables. Data were stored and analyzed using the statistics software IBM SPSS STATISTICS 21.0.
RESULTS
Between September 2009 and June 2015, 153 cases of VM were identified; of these, 121 were identified as mild with at least one ventricle measuring 10 to 15 mm at first visit, excluding 32 cases with ventricular dilation >15 mm. Ventricular dilation measurement varied from 10.0 to 14.1 and 10.0 to 15.0 mm in cases of isolated and complex VM, respectively ( Figure 2 ). Fifty-six (46.3%) of these 121 fetuses exhibited no other anomalies at initial US and were classified as isolated VM, and 65 (53.7%) fetuses had additional identifiable findings ( Table 1) .
The mean maternal age was 26.6 years (SD 6.5) for cases of isolated VM and 27.1 years (SD 6.9) in cases of complex VM. The mean gestational age at initial presentation was 24.7 weeks (SD 4.0, range 18-33 weeks) and 24.3 weeks (SD 4.8, range 16-36 weeks) in cases of isolated and complex VM, respectively. Twenty twin pregnancies were included. Five presented as cases of isolated VM (1 dichorionic, 4 monochorionic), and 14 presented with complex VM (4 dichorionic, 10 monochorionic); there was 1 unknown. In all but one twin pregnancy, only one fetus was affected. The overall fetal sex ratio was 1.34 (63 male and 47 female) with 11 cases of unidentified sex. Fetal sex ratio was 1.45 in cases of isolated VM and 1.26 in cases of complex VM. Pregnancy outcome data were available for 91 cases (76.9%). Pregnancy resulted in live births in 36 (97.3%) of isolated VM cases and 37 (66.1%) of complex VM cases. One (2.7%) case of isolated VM ended with termination. In the case of complex VM, 13 (23.2%) resulted in termination and 6 (10.7%) were classified as intrauterine death (IUD) ( Table 2) .
Ventricular dilation was characterized in all cases. Among the 56 fetuses with isolated VM, the mean atrial width was 10.6 mm (SD 0.9). Forty-two (75.0%) had unilateral ventricular enlargement, and 14 (25.0%) exhibited bilateral enlargement. Twenty-seven (55.1%) fetuses had symmetrical enlargement of the ventricular diameter, and 22 (44.9%) had asymmetrical ventricle enlargement. Cases of complex VM displayed a mean ventricular atrial width of 11.7 mm (SD 1.5). Thirty (46.2%) cases of complex VM were characterized as unilateral ventricular dilation, compared with 35 (53.8%) cases with bilateral enlargement. Forty-six (78.0%) had symmetrical ventricular dilation, and 13 (22.0%) had asymmetric measurements between the two ventricles (Table 3) .
Forty-seven (38.8%) women underwent fetal MR imaging following the identification of VM -24 (42.9%) of isolated and 23 (35.4%) of complex VM cases ( Table 4 ). The mean gestational age at follow-up MRI was 29.7 weeks (range 25-34 weeks) in cases of isolated VM, and 27.9 weeks (range 20-37 weeks) in cases of complex VM. In 3/24 (12.5%) cases of isolated VM and 18/23 (78.3%) cases of complex VM MRI was able to provide additional information by either confirming suspected US findings or identifying additional fetal anomalies ( Table 1 ). The additional findings identified in cases of isolated VM included possible decreased gyration of the fetal cerebral cortex in the first case, which had an unknown outcome. Colpocephaly was identified in the second case, resulting in a live birth at 36 weeks' gestation with subsequent infant death at greater than 1 week of age. Finally, parenchymal atrophy was noted in the third case, which resulted in a termination at 27 weeks' gestation. In total, 39 (34.8%) cases had at least some form of chromosome abnormality testing whether karyotype analysis, microarray, or FISH. Abnormal genetic test results were identified in 4/9 (44.4%) and 8/30 (26.7%) of isolated and complex VM cases, respectively (Table 4) . Chromosomal abnormalities in the cases of isolated VM included two cases of trisomy 21, one partial duplication of chromosome 7 and one inversion of chromosome 9 (Table 1) . One case of trisomy 21 resulted in a live birth at 31 weeks' gestation, and the other was an intrauterine death. The duplication of chromosome 7 resulted in a live birth at 39 weeks' gestation, and the chromosome 9 inversion resulted in a live birth at 27 weeks' gestation. The eight chromosomal abnormalities identified in cases of complex VM included long contiguous homozygosity of chromosome 8, duplication of chromosome 5, duplication of chromosome 4 with terminal deletion of chromosome 12, microdeletion of chromosome 4, trisomy 18, and three cases of trisomy 21 (Table 1) .
Twenty-five (22.3%) women underwent serological infection testing. No woman in either the isolated VM or complex VM group had a positive infection screen (Table 4) .
DISCUSSION
Our study found that comprehensive follow-up testing in cases of imVM using fetal brain MRI, chromosomal abnormality testing, and screening for congenital infection may be useful in better characterizing fetal prognosis and pregnancy management.
Previous reports from the literature regarding test results are extremely heterogeneous owing to the inconsistent grouping of isolated and complex VM as well as mild, moderate, and severe measurements. In addition, findings may be presented as a proportion of the total study group, as opposed to the subset actually tested, which is the minimum rate because it assumes that all untested cases were without findings. These discrepancies introduce bias and makes findings difficult to compare across studies.
Follow-up fetal MRI
Follow-up fetal MRI provided additional information in 3/24 (12.5%) isolated VM cases who had imaging -3/56 (5.4%) of all imVM cases -and confirmed imVM in the rest that is reassuring. MRI was also able to provide additional findings in cases of complex VM, although the clinical significance is debatable owing to the strong prognostic indicators of additional fetal abnormalities already identified at US.
Multiple studies have demonstrated that MRI may add important information to that obtained at initial US in cases of imVM. 12, 20, 21, [24] [25] [26] Review of the contemporary literature found detection rates of clinically relevant fetal abnormality by MRI not seen at US ranging from 1.1% to 8.9% 5, 9, 16, 20, 24, 37 in cases of imVM. Interpretation of previous findings as to the utility of MRI in cases of imVM is complicated by heterogeneity of study designs, subjective definition of clinically significant findings, and inconsistent calculations of findings. It is commonly accepted that MRI is able to detect particular anomalies such as cortical gyral abnormalities that are too subtle for US recognition. 38 Even though MRI may provide superior imaging, our MRI detection rate of abnormalities not seen on US was lower than some comparable studies, possibly because of the skill of US scanning at our tertiary referral center. Even with this low detection rate, MRI was able to better characterize significant brain anomalies that were not seen at US, as well as provide reassurance in cases of truly isolated VM. Although MRI is a significant resource, we recommend its use in cases of imVM in order to provide the most information to families and physicians when making pregnancy management decisions. In cases where MRI is not utilized, repeated US scanning by skilled technicians is recommended as fetal brain abnormalities can develop with ongoing pregnancy and may lead to the detection of additional anomalies as gestation progresses.
Chromosome abnormality testing
Four of the nine cases of imVM that had genetic testing were found to have an underlying genetic abnormality. Because only a small subset of our study population had genetic testing, we report a chromosomal abnormality minimum rate of 7.1% (4/56) in cases of imVM. This finding is comparable with previous research, although would be expected to increase with more comprehensive testing of the study population. In a review of the literature, Gaglioti et al. described the presence of aneuploidy in 3% to 15% of cases of imVM. 8 This is comparable with the systematic review of imVM performed by Devaseelan et al., which identified an overall rate of chromosomal abnormality of 5% 19 and the meta-analysis by Pagani et al. including over 1200 fetuses with imVM that identified abnormal karyotype in 4.7%. 5 The most recent data are presented by D'Addario and Rossi, citing an average incidence of aneuploidy in 2.7% (range 0-26%) of cases of imVM. 21 The wide range is possibly caused by varying maternal age, which was often not reported in the included studies.
Although there is varying incidence of chromosomal abnormalities in cases of imVM, there clearly is an association. Given this, and the large impact genetic abnormality has on fetal prognosis, the benefits of genetic testing seem to outweigh the risks of amniocentesis. We recommend chromosome abnormality testing in all cases of VM, including imVM.
Maternal serologic infection screening
Serologic infection screening was performed in 13 cases of isolated VM to investigate the presence of primary maternal infection. There were no positive cases of infection identified in the study population.
Multiple congenital viral infections such as CMV, parvovirus B19, and toxoplasmosis have been associated with mild VM. These infections are often associated with additional significant abnormalities of the fetus. CMV infection is associated with VM as well as microcephaly, increased periventricular echogenicity or calcifications, and cortical and cerebellar findings.
39 VM may also be present in parvovirus with the major fetal findings being hydrops fetalis and anemia. 40 Herpes virus rarely causes intrauterine infection, with the majority of infections occurring peripartum without prenatal effects. 43, 44 The clinical presentation of fetal HSV infection is characterized by CNS destruction, along with ophthalmologic findings and cutaneous manifestations. 43 HSV screening is complicated by the poor specificity of a single serum antibody screen for both HSV1 and HSV2 infection, as well as the test itself having low positive predictive value. 45 There were two women in the isolated VM group and one woman in the complex VM group who had positive HSV1/2 IgM serology results. Owing to the reasons stated regarding HSV infection and testing, these were not considered positive serology results for this study.
Although not investigated in our study, of current interest in prenatal health is congenital Zika syndrome. Fetal neurological manifestations of Zika infection include microcephaly, VM, cerebellar hypoplasia, lissencephaly, and arthrogryposis. 46 The International Society of Ultrasound in Obstetrics and Gynecology interim guidance on US for Zika virus in pregnancy recommends referral to a specialist center for assessment in cases of fetal brain abnormality, including VM. 47 Although there currently is no evidence of an association between Zika infection and imVM specifically, it is possible and should be investigated further especially in cases where clinical suspicion is raised in the context of travel to a high-risk region, clinical or laboratory evidence of disease, or concurrent microcephaly.
Previous studies have recommended selective infection screening in all cases of VM, even when low incidence of infection was reported. 17, 34 Although there were no cases of maternal infection in our study population, infection screening should be considered in cases of imVM. Given the previously reported association of infection with imVM, the significant impact on prognosis, existence of treatment options, and the simplicity and safety of screening, we do recommend TORCH testing, focusing on CMV, parvovirus B19, and toxoplasmosis. We acknowledge the limitations of this study. It involved a limited number of patients and was retrospective with the presence of potential bias and confounding that is inherent to this study design. Study power was also affected by a lack of comprehensive, consistent provision of ancillary testing. Follow-up during pregnancy was limited, and we did not include findings from serial US or MRI scans in our study. This is particularly important given the fact that previous research has demonstrated identification of additional abnormalities at later US scans and progression of ventricular dilation as having major prognostic impact. 17, 20, 21, 24 Additionally, longterm follow-up or outcome data for our patients, for example, neurodevelopmental outcomes was not available.
CONCLUSION
Ventriculomegaly is the most common fetal brain abnormality identified, yet its significance is incompletely understood. Our study population demonstrated the utility of follow-up MRI and chromosome abnormality testing in cases of imVM. Infection screening was not found to provide information in our limited study population, although previously detected rates of infection may be below our detection threshold. Maternal infection screening should be considered as a component of comprehensive follow-up care in cases of imVM. Every patient and pregnancy is unique and requires specialized care, all decisions must be made between the healthcare provider and patient in light of existing evidence.
